Overview

Dexamethasone Intravitreal Implant for the Treatment of Persistent Diabetic Macular Edema

Status:
Completed
Trial end date:
2018-10-24
Target enrollment:
Participant gender:
Summary
Laser photocoagulation and intravitreal anti-vascular growth factor injections are commonly used treatment options for individuals with diabetic macular edema. However, some patients continue to experience persistent diabetic macular edema and poor vision despite continued laser and/or anti-vegf therapy. Recent clinical trials suggest that due to inflammatory mediators dexamethasone intravitreal implant (0.7mg) may be a good alternative therapy for individuals unresponsive to laser photocoagulation or intravitreal anti-vascular growth factor injections. The purpose of this research study is to compare the effectiveness of using a dexamethasone steroid implant versus monthly intravitreal anti-VEGF injections for research participants with persistent diabetic macular edema (DME).
Phase:
Phase 4
Details
Lead Sponsor:
California Retina Consultants
Collaborator:
Allergan
Treatments:
Aflibercept
BB 1101
Bevacizumab
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Endothelial Growth Factors
Ranibizumab